News - Alcon

Filter

Current filters:

Alcon

Popular Filters

Novartis 1st-qtr net profit flat, sales shy of forecasts

Novartis 1st-qtr net profit flat, sales shy of forecasts

24-04-2014

Swiss drug major Novartis posted a solid set of first-quarter 2014 financials this morning, showing that…

AlconFinancialNovartisPharmaceuticalSandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon and Richard Francis as Division Head, Sandoz

22-04-2014

Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and…

AlconBoardroomNorthern EuropeNovartisPharmaceuticalSandoz

First Asian approval for ophthalmic drug Jetrea, in Malaysia

18-04-2014

Belgian biotech firm ThromboGenics NV revealed today that Jetrea (ocriplasmin) has been approved in Malaysia…

AlconAsia-PacificBiotechnologyJetreaMalaysiaNovartisOphthalmicsRegulationThromboGenics

ThromboGenics to begin Jetrea study in USA

ThromboGenics to begin Jetrea study in USA

04-03-2014

Belgium-based biopharma firm ThromboGenics will soon initiate a US Phase IV study with Jetrea (ocriplasmin).

AlconBelgiumJetreaOphthalmicsPharmaceuticalResearchThromboGenics

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

ThromboGenics’ Jetrea gets positive reimbursement opinion in France

17-01-2014

Belgian biotech firm ThromboGenics says that the Transparency Commission of the French National Health…

AlconBiotechnologyJetreaNovartisOphthalmicsPricingThromboGenics

Alcon and ThromboGenics launch Jetrea in Canada

21-11-2013

ThromboGenics NV (Euronext Brussels: THR) and its partner Alcon, the ophthalmic unit of Novartis (NOVN:…

AlconBiotechnologyCanadaJetreaMarkets & MarketingOphthalmicsRegulationThromboGenics

Germany’s G-BA confirms benefits of ThromboGenics’ Jetrea for VMT

18-10-2013

Belgian biotech firm ThromboGenics says that the Final Early Benefit Assessment from the German Federal…

AlconBiotechnologyEuropeJetreaNovartisOphthalmicsPricingRegulationThromboGenics

ThromboGenics' Jetrea gets initial NICE recommendation for VMT

12-06-2013

Belgium-based biopharma company ThromboGenics (Euronext Brussels: THR) said this morning (June 12) that…

AlconEuropeJetreaNovartisOphthalmicsPharmaceuticalPricingRegulationThromboGenics

Alcon and ThromboGenics Jetrea launched in Denmark and Sweden

28-05-2013

Belgium's ThromboGenics (Euronext Brussels: THR) says that its partner Alcon, the eye care subsidiary…

AlconEuropeJetreaMarkets & MarketingNovartisOphthalmicsPharmaceuticalThromboGenics

US FDA approves Alcon's Simbrinza, a fixed-combination therapy for glaucoma

22-04-2013

Swiss drug major Novartis' (NOVN: VX) eye care division Alcon on Friday (April 19) received US Food and…

AlconNorth AmericaNovartisOphthalmicsPharmaceuticalRegulationSimbrinza

EU approval of Jetrea triggers a 45 million-euro milestone for ThromboGenics from Alcon

18-03-2013

The European Commission has approved Swiss drug major Novartis' (NOVN: VX) Alcon ophthalmic unit's Jetrea…

AlconEuropeFinancialJetreaNovartisOphthalmicsPharmaceuticalRegulationThromboGenics

Alcon's Nevanac accepted for NHS use in Scotland

12-11-2012

Ophthalmic specialist Alcon, a part of Swiss drug major Novartis (NOVN: VX), said yesterday that its…

AlconEuropeNevanacNovartisOphthalmicsPharmaceuticalPricingRegulation

Ph III trials show Novartis' Jetrea improves vitreomacular traction

17-08-2012

Swiss drug major Novartis (NOVN: VX) that the New England Journal of Medicine (NEJM) this week published…

AlconJetreaNovartisocriplasminOphthalmicsPharmaceuticalResearchThromboGenics

FDA advisory panel backs approval of ThromboGenics' ocriplasmin for VMA

29-07-2012

Belgian biopharmaceutical firm ThromboGenics NV (Euronext Brussels: THR) says that the US Food and Drug…

AlconBiotechnologyNorth AmericaNovartisocriplasminOphthalmicsRegulationThromboGenics

Novartis beats forecasts, despite generic and currency hits

19-07-2012

Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion,…

AlconFinancialGenericsNovartisPharmaceuticalSandoz

Novartis unit buys rights to ThromboGenics eye drug

16-03-2012

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered…

AlconBiotechnologyLicensingNovartisocriplasminOphthalmicsPharmaceuticalThromboGenics

Novartis says it is on track to deliver growth goals, helped by Alcon acquisition

13-09-2011

In an investors’ update yesterday, Swiss drug major Novartis (NOVN: VX) presented its long-term…

AlconFinancialNovartisOphthalmicsPharmaceuticalResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top